Guest: Dr. Ted W. Love
Presenter: Neal Howard
Guest Bio: Dr. Love joined GBT in June 2014 as President and Chief Executive Officer with broad leadership and management experience in the biotech/pharmaceutical industry. Before that, he was Executive Vice President, Research and Development and Technical Operations at Onyx Pharmaceuticals, Inc., where he played an instrumental role in initiating and completing several of Onyx’s first Phase 3 clinical trials. Prior to Onyx, Dr. Love served as President, Chief Executive Officer and Chairman of Nuvelo, Inc., where he led growth of the company to a market capitalization of $1 billion. Prior to that, he served as Senior Vice President, Development at Theravance, Inc. Earlier in his career, Dr. Love held a number of senior management positions in medical affairs and product development at Genentech, where he served as Chairman of Genentech’s Product Development Committee. Dr. Love has served as a consultant in medicine in the Department of Cardiology at the Massachusetts General Hospital. He currently serves on the board of directors of Amicus Therapeutics, Inc., and Cascadian Therapeutics (formerly Oncothyreon). Dr. Love holds a B.A. in molecular biology from Haverford College and an M.D. from Yale Medical School. He completed a residency in internal medicine and a fellowship in cardiology at the Massachusetts General Hospital.
Segment Overview: Dr. Ted W. Love, CEO of Global Blood Therapeutics, Inc. (GBT) discusses sickle cell disease (SCD), the drug Voxelotor currently in development, and the social issues surrounding treating patients with SCD.